The Golden OX Listed Companies Summit / Award Ceremony of The 21st Golden OX Prize, sponsored by China Securities Journal, was successfully held in Beijing on October 31, 2019. Asymchem Laboratories Co., Ltd. (SHE:002821.SZ; “Asymchem”) was honored to receive the awards “The Golden OX Prize of the Most Valuable Chinese Listed Companies” and “The Golden OX Prize of Secretary of the Board” for the second time. The prize fully affirmed Asymchem for its overall strength and consistent development in the capital market.
Award ceremony of the 21st Golden OX Prize of Listed Company
Golden OX Listed Companies Summit has been held for 21 years since 1999 and has become aninfluential economic forum focusing on the real economy and high quality development of listed companies.
Candidates of the Golden OX Prize should meet the qualification evaluation in five aspects of economic profits: asset quality, insolvency risk, development potential, and market performance through qualitative research and quantitative analysis.
The evaluation of The Golden OX Prize of the Most Valuable Chinese Listed Companies focuses more on the continued profitability and stable return on investment of listed companies, emphasizing endogenous growth as an important driving force for listed companies. The Golden OX Prize has witnessed the rapid development of China's economy and capital market, recorded the excellent performance of listed companies in past years, and continuously attracted the attention of the heads of listed companies, the secretary of the Board of Directors and other senior management. This award ceremony honored those who have made outstanding achievements in the past few years and encouraged high-quality listed companies to play a greater role in China's economy.
Asymchem receives the Golden OX Prize of Listed Company
The Summit, held with the theme of high-quality development of listed companies, discussed topics such as the macroeconomic situation and the regression of the value of listed companies in order to enhance the value and progress of listed companies. China's novel drug R&D efficiency and scale has increased rapidly in recent years and local innovative pharmaceutical enterprises have expanded into global markets. Asymchem has been making continued efforts in the innovation and application of core technologies such as flow chemistry technology and bioenzyme catalysis, along with its professional services. Asymchem occupies a great share in the CDMO field of innovative drugs with consistently growing customer orders and an increasing number of projects year after year. The company has now built an integrated service system, including domestic innovative drug CMC services, formulation development and production, clinical research of innovative drugs, biological testing and drug registration and filing. Meanwhile, the company has also been gradually upgrading the direction of multi-dimensional strategic development, continuing to propel into new markets and business planning, and improving its capabilities to provide one stop “CMC-Clinical research” services.
Golden OX Prize of Most Valuable Chinese Listed Companies
The Golden OX Prize of Secretary of the Board
Since going public in 2016, Asymchem has been widely recognized in the capital markets. With excellent operation and profitability, rigorous financial management, and high quality information security, the company has been included in the “MSCI China A-share Onshore Index,” “Sample Stocks on the Small and Medium-sized Board”, “China Securities 500 Index” and the “FTSE Russell’s Global Indexes”, “China Biomeidcal Industry Barometer (CBIB)”. Asymchem was awarded the “2018 Top 50 of China's Small and Medium-sized Board Listed Companies” and “2017 Golden OX Prize of the Most Valuable Chinese Listed Companies”. The company was ranked in the “Top 10 Management Team of China’s Small and Medium-sized Board Listed Companies”, and “2019 Nifty 100 of China A Shares”, and “Board of Directors of China's Small and Medium-sized Board Listed Companies With Best Investor Relations”.
Since its establishment 20 years ago, Asymchem plays a leading role in the CDMO industry with its commitment to green pharmaceutical development through technological innovation. In an industry where the global pharmaceutical market grows steadily and professional division of labor is maturing, Asymchem will make continued efforts to create greater economic and social benefits and promote the healthy development of the global pharmaceutical industry.
Scene from the summit